
ATTO Stock Forecast & Price Target
ATTO Analyst Ratings
Bulls say
Attovia Therapeutics is viewed favorably because its ATTOBODY platform can generate differentiated mono-, bi-, and trispecific biologics against validated immune targets, potentially creating a durable pipeline in large, underserved I&I markets. ATTO-1310 already showed promising 4-week itch reduction signals and is modeled to reach 49,469 treated patients with $1.875 billion in U.S. sales across CPUO, high-itch AD, cholestatic pruritus, and CKD-aP, while YTE half-life extension could support quarterly maintenance dosing and better convenience. ATTO-2306 and ATTO-1091 add further upside through rational multi-target designs in AD and IBD, with early preclinical data and upcoming 2027 clinical starts supporting a long runway for value creation.
Bears say
Attovia Therapeutics is viewed skeptically because its lead programs face a crowded competitive landscape in AD and IBD, where IL-13, IL-31, and bispecific/trispecific approaches have already raised the efficacy bar and may limit differentiation. The company also carries meaningful clinical risk: the IL-31 ligand strategy may not outperform receptor antagonists, ATTO-2306’s potency advantages may not translate in the clinic, and ATTO-1310 may have fewer advantages over Nemluvio beyond dosing frequency. With no marketed products and no revenues, it may need additional capital to fund ongoing R&D and commercialization, while setbacks such as safety signals, regulatory delays, or weaker-than-expected efficacy could materially reduce the probability of success.
This aggregate rating is based on analysts' research of Attovia Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ATTO Analyst Forecast & Price Prediction
Start investing in ATTO
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Attovia Therapeutics Inc (ATTO) Forecast
ATTO Analyst Forecast & Price Prediction
Start investing in ATTO
Order type
Buy in
Order amount
Est. shares
0 shares